AI Science Tracker
EN

Fujian University of Traditional Chinese Medicine

1 discovery from 2024

Discoveries

Consensus-learned lung-cancer groups associate with survival

Source check: Source checked. Not independent scientific confirmation.

Finding: An ensemble of seven multi-omics clustering methods identified three lung-adenocarcinoma groups. The LIMOC2 group had shorter observed overall survival, with a similar ordering reported after template-based assignment in two additional archived cohorts. This is an exploratory model-defined clinical association, not proof of a biological taxonomy or vaccine/drug response.

Technology: LIMOC; consensus multi-omics clustering including CIMLR and MoCluster

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Data-fitted multi-omics partitions generate the patient groups whose clinical survival distributions are compared; dimensionality-reduction graphics alone are not the enabling evidence.
Test and result
Primary indexed Methods 2.2 describe seven fitted clustering algorithms, a co-assignment consensus matrix and hierarchical consensus grouping. The top subtype-associated expression features supplied nearest-template assignments in a meta-cohort and GSE72094. Results3.1 report the survival ordering.
Limitation / still unknown
The subtype labels and selected features depend on preprocessing, immune-feature selection and consensus choices. Exact cohort-level numerical effect sizes and supplemental overlap checks were not inspected, so no independent causal or forecasting claim is made. Antigen immunogenicity, vaccine suitability and predicted compound response are not measured treatment effects and are outside the represented result. Primary PubMed records April24; the migrated SPJ publisher page says April30. The earlier documented article date is used with this conflict retained, not as an absolute-priority claim.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://spj.science.org/doi/10.1016/j.csbj.2024.04.056

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Exact primary identity and scoped safe computational/clinical Methods and high-level Results; evidence access distinguished in case ledger; no operational laboratory procedures evaluated.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.